Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 30/11/2018 n/a 21/11/2018 PL. 14/11/2018 n/a

Transcription

1 Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected 3 amended on IA/0032 B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure 30/11/2018 n/a N/0031 Minor change in labelling or package leaflet not connected with the SPC (Art Notification) 21/11/2018 PL IA/0030 B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting 14/11/2018 n/a 1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures. 2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union

2 material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) T/0028 Transfer of Marketing Authorisation 23/08/ /09/2018 SmPC, Labelling and PL R/0027 Renewal of the marketing authorisation. 28/06/ /08/2018 SmPC and PL Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. / /05/2018 n/a PRAC Recommendation - maintenance II/0025/G This was an application for a group of variations. B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer 18/01/ /08/2018 SmPC, Annex II and PL EMA/7554/2019 Page 2/6

3 responsible for importation and/or batch release - Not including batch control/testing IB/0024 B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation 26/07/2017 n/a IB/0023/G This was an application for a group of variations. 22/05/2017 n/a B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate / /05/2017 n/a PRAC Recommendation - maintenance IB/0021 B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) 10/01/ /07/2017 SmPC, Annex II and Labelling IB/0020 B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data 14/12/2016 n/a / /10/2016 n/a PRAC Recommendation - maintenance EMA/7554/2019 Page 3/6

4 IG/0720 B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing 16/08/ /07/2017 Annex II and PL / /04/2016 n/a PRAC Recommendation - maintenance IA/0017 A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient 13/04/2016 n/a IA/0016 A.7 - Administrative change - Deletion of manufacturing sites 23/03/2016 n/a IB/0015 B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) 04/03/ /07/2016 SmPC, Annex II, Labelling and PL / /11/2015 n/a PRAC Recommendation - maintenance II/0007/G This was an application for a group of variations. 24/09/2015 n/a Submission of studies AC-055C301/DUAL-1 and AC-055C302/DUAL-2, two completed Phase 3 studies in patients with digital ulcers associated with systemic sclerosis. An updated RMP has been submitted EMA/7554/2019 Page 4/6

5 accordingly (latest approved version is v.9.0). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority IG/0612 B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing 07/09/ /07/2016 Annex II and PL II/0008 Update of section 4.5 of the SmPC in order to update the safety information on drug-drug interaction reporting no interaction between and hormonal contraceptives. Furthermore the MAH took the occasion to updated section 5.3 of the SmPC to introduce minor correction on two ratios revised based on data already assessed during Marketing Authorisation Application. In addition the MAH took the opportunity to make some linguistic improvements and correct typographical errors to the Annexes in various languages (BG, CS, DA, DE, EL, ES, ET, FI, FR, HR, HU, IT, LT, LV, MT, PL, PT, RO, SK, SL, SV) and to update administrative information for its local representatives for Estonia, Ireland, Latvia, Lithuania, Malta and United Kingdom. 06/08/ /07/2016 SmPC and PL Macitentan 10 mg once daily did not affect the pharmacokinetics of an oral contraceptive (norethisterone 1 mg and ethinyl estradiol 35 µg). C.I.4 - Change(s) in the SPC, Labelling or PL due to EMA/7554/2019 Page 5/6

6 new quality, preclinical, clinical or pharmacovigilance data / IA/0009 B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold 21/05/ /07/2015 Please refer to -PSUSA EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation 23/06/2015 n/a PSUV/0003 Periodic Safety Update 20/11/ /01/2015 SmPC and PL Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUV/0003. IA/0005 IB/0002 C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation 17/09/ /01/2015 SmPC, Labelling and PL 16/07/2014 n/a N/0001 Minor change in labelling or package leaflet not connected with the SPC (Art Notification) 28/05/ /01/2015 PL EMA/7554/2019 Page 6/6